Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 44 entries
Sorted by: Best Match Show Resources per page
Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease.

Journal of health psychology

Montalescot L, Speyer E, Legrand K, Ayav C, Combe C, Stengel B, Untas A.
PMID: 32772863
J Health Psychol. 2020 Aug 10;1359105320949921. doi: 10.1177/1359105320949921. Epub 2020 Aug 10.

The Family Relationship Index (FRI) measures family cohesion, expressiveness and conflict. This study aimed to investigate its reliability and validity in patients with chronic kidney disease (CKD). Confirmatory factor analysis was performed on 1657 patients and on subgroups according...

Cite
Montalescot L, Speyer E, Legrand K, et al. Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. J Health Psychol. 2020;1359105320949921doi: 10.1177/1359105320949921.
Montalescot, L., Speyer, E., Legrand, K., Ayav, C., Combe, C., Stengel, B., & Untas, A. (2020). Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. Journal of health psychology, 1359105320949921. https://doi.org/10.1177/1359105320949921
Montalescot, Lucile, et al. "Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease." Journal of health psychology vol. (2020): 1359105320949921. doi: https://doi.org/10.1177/1359105320949921
Montalescot L, Speyer E, Legrand K, Ayav C, Combe C, Stengel B, Untas A. Reliability and validity of the French adaptation of the Family Relationship Index-short form in patients' with chronic kidney disease. J Health Psychol. 2020 Aug 10;1359105320949921. doi: 10.1177/1359105320949921. Epub 2020 Aug 10. PMID: 32772863.
Copy Download .nbib Format: NLM
Current Topics.

The Indian medical gazette

Montalescot G.
PMID: 29003495
Ind Med Gaz. 1902 Aug;37(8):320-323.

No abstract available.

Cite
Montalescot G. Current Topics. Ind Med Gaz. 1902;37(8):320-323
Montalescot, G. (1902). Current Topics. The Indian medical gazette, 37(8), 320-323.
Montalescot. "Current Topics." The Indian medical gazette vol. 37,8 (1902): 320-323.
Montalescot G. Current Topics. Ind Med Gaz. 1902 Aug;37(8):320-323. PMID: 29003495; PMCID: PMC5155922.
Copy Download .nbib Format: NLM
Low molecular weight heparin use in percutaneous coronary intervention.

Critical pathways in cardiology

Choussat R, Collet JP, Dalby M, Montalescot G.
PMID: 18340300
Crit Pathw Cardiol. 2002 Sep;1(3):180-3.

No abstract available.

Cite
Choussat R, Collet JP, Dalby M, et al. Low molecular weight heparin use in percutaneous coronary intervention. Crit Pathw Cardiol. 2002;1(3):180-3
Choussat, R., Collet, J. P., Dalby, M., & Montalescot, G. (2002). Low molecular weight heparin use in percutaneous coronary intervention. Critical pathways in cardiology, 1(3), 180-3.
Choussat, Rémi, et al. "Low molecular weight heparin use in percutaneous coronary intervention." Critical pathways in cardiology vol. 1,3 (2002): 180-3.
Choussat R, Collet JP, Dalby M, Montalescot G. Low molecular weight heparin use in percutaneous coronary intervention. Crit Pathw Cardiol. 2002 Sep;1(3):180-3. PMID: 18340300.
Copy Download .nbib Format: NLM
Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East.

Circulation journal : official journal of the Japanese Circulation Society

Silvain J, Kerneis M, Collet JP, Montalescot G.
PMID: 25744630
Circ J. 2015;79(1):223. doi: 10.1253/circj.CJ-66-0110.

No abstract available.

Cite
Silvain J, Kerneis M, Collet JP, et al. Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East. Circ J. 2015;79(1):223doi: 10.1253/circj.CJ-66-0110.
Silvain, J., Kerneis, M., Collet, J. P., Montalescot, G. (2015). Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East. Circulation journal : official journal of the Japanese Circulation Society, 79(1), 223. https://doi.org/10.1253/circj.CJ-66-0110
Silvain, Johanne, et al. "Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East." Circulation journal : official journal of the Japanese Circulation Society vol. 79,1 (2015): 223. doi: https://doi.org/10.1253/circj.CJ-66-0110
Silvain J, Kerneis M, Collet JP, Montalescot G. Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East. Circ J. 2015;79(1):223. doi: 10.1253/circj.CJ-66-0110. PMID: 25744630.
Copy Download .nbib Format: NLM
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis.

Clinical research in cardiology : official journal of the German Cardiac Society

Orban M, Kleeberger J, Ouarrak T, Freund A, Feistritzer HJ, Fuernau G, Geisler T, Huber K, Dudek D, Noc M, Montalescot G, Neumer A, Haller P, Clemmensen P, Zeymer U, Desch S, Massberg S, Schneider S, Thiele H, Hausleiter J.
PMID: 33999281
Clin Res Cardiol. 2021 Sep;110(9):1493-1503. doi: 10.1007/s00392-021-01866-3. Epub 2021 May 17.

AIMS: The aim of this pooled sub-analysis of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) and Culprit Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock (CULPRIT-SHOCK) trial was to compare the clinical outcome of patients...

Cite
Orban M, Kleeberger J, Ouarrak T, et al. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clin Res Cardiol. 2021;110(9):1493-1503doi: 10.1007/s00392-021-01866-3.
Orban, M., Kleeberger, J., Ouarrak, T., Freund, A., Feistritzer, H. J., Fuernau, G., Geisler, T., Huber, K., Dudek, D., Noc, M., Montalescot, G., Neumer, A., Haller, P., Clemmensen, P., Zeymer, U., Desch, S., Massberg, S., Schneider, S., Thiele, H., & Hausleiter, J. (2021). Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clinical research in cardiology : official journal of the German Cardiac Society, 110(9), 1493-1503. https://doi.org/10.1007/s00392-021-01866-3
Orban, Martin, et al. "Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis." Clinical research in cardiology : official journal of the German Cardiac Society vol. 110,9 (2021): 1493-1503. doi: https://doi.org/10.1007/s00392-021-01866-3
Orban M, Kleeberger J, Ouarrak T, Freund A, Feistritzer HJ, Fuernau G, Geisler T, Huber K, Dudek D, Noc M, Montalescot G, Neumer A, Haller P, Clemmensen P, Zeymer U, Desch S, Massberg S, Schneider S, Thiele H, Hausleiter J. Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis. Clin Res Cardiol. 2021 Sep;110(9):1493-1503. doi: 10.1007/s00392-021-01866-3. Epub 2021 May 17. PMID: 33999281; PMCID: PMC8405498.
Copy Download .nbib Format: NLM
Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis.

European journal of preventive cardiology

Gerardin B, Guedeney P, Bellemain-Appaix A, Levasseur T, Mustafic H, Benamer H, Monsegu J, Lamhaut L, Montalescot G, Aubry P, Collet JP.
PMID: 34021577
Eur J Prev Cardiol. 2021 May 22;28(6):679-686. doi: 10.1177/2047487320943001.

AIMS: Limited data exist regarding the incidence and aetiology of life-threatening events such as major cardiac events or exertional heat stroke during long-distance races. We aimed to provide an updated incidence, etiology and prognosis of life-threatening events during long-distance...

Cite
Gerardin B, Guedeney P, Bellemain-Appaix A, et al. Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. Eur J Prev Cardiol. 2021;28(6):679-686doi: 10.1177/2047487320943001.
Gerardin, B., Guedeney, P., Bellemain-Appaix, A., Levasseur, T., Mustafic, H., Benamer, H., Monsegu, J., Lamhaut, L., Montalescot, G., Aubry, P., Collet, J. P. (2021). Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. European journal of preventive cardiology, 28(6), 679-686. https://doi.org/10.1177/2047487320943001
Gerardin, Benoît, et al. "Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis." European journal of preventive cardiology vol. 28,6 (2021): 679-686. doi: https://doi.org/10.1177/2047487320943001
Gerardin B, Guedeney P, Bellemain-Appaix A, Levasseur T, Mustafic H, Benamer H, Monsegu J, Lamhaut L, Montalescot G, Aubry P, Collet JP. Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. Eur J Prev Cardiol. 2021 May 22;28(6):679-686. doi: 10.1177/2047487320943001. PMID: 34021577.
Copy Download .nbib Format: NLM
The Enduring Legacy of Failed Revascularization Trials.

Journal of the American College of Cardiology

Dauerman HL, Tijssen JGP, Montalescot G.
PMID: 34736564
J Am Coll Cardiol. 2021 Nov 09;78(19):1886-1889. doi: 10.1016/j.jacc.2021.08.059.

No abstract available.

Cite
Dauerman HL, Tijssen JGP, Montalescot G. The Enduring Legacy of Failed Revascularization Trials. J Am Coll Cardiol. 2021;78(19):1886-1889doi: 10.1016/j.jacc.2021.08.059.
Dauerman, H. L., Tijssen, J. G. P., & Montalescot, G. (2021). The Enduring Legacy of Failed Revascularization Trials. Journal of the American College of Cardiology, 78(19), 1886-1889. https://doi.org/10.1016/j.jacc.2021.08.059
Dauerman, Harold L, et al. "The Enduring Legacy of Failed Revascularization Trials." Journal of the American College of Cardiology vol. 78,19 (2021): 1886-1889. doi: https://doi.org/10.1016/j.jacc.2021.08.059
Dauerman HL, Tijssen JGP, Montalescot G. The Enduring Legacy of Failed Revascularization Trials. J Am Coll Cardiol. 2021 Nov 09;78(19):1886-1889. doi: 10.1016/j.jacc.2021.08.059. PMID: 34736564.
Copy Download .nbib Format: NLM
Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients.

European journal of clinical investigation

Hammoudi N, Ceccaldi A, Haymann JP, Guedeney P, Nicolas-Jilwan F, Zeitouni M, Montalescot G, Lionnet F, Isnard R, Hatem SN.
PMID: 34390499
Eur J Clin Invest. 2021 Aug 14;e13664. doi: 10.1111/eci.13664. Epub 2021 Aug 14.

BACKGROUND: The underlying mechanisms of exercise intolerance in sickle cell anaemia (SCA) patients are complex and not yet completely understood. While latent heart failure at rest could be unmasked upon exercise, most previous studies assessed cardiac function at rest....

Cite
Hammoudi N, Ceccaldi A, Haymann JP, et al. Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. Eur J Clin Invest. 2021;e13664doi: 10.1111/eci.13664.
Hammoudi, N., Ceccaldi, A., Haymann, J. P., Guedeney, P., Nicolas-Jilwan, F., Zeitouni, M., Montalescot, G., Lionnet, F., Isnard, R., & Hatem, S. N. (2021). Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. European journal of clinical investigation, e13664. https://doi.org/10.1111/eci.13664
Hammoudi, Nadjib, et al. "Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients." European journal of clinical investigation vol. (2021): e13664. doi: https://doi.org/10.1111/eci.13664
Hammoudi N, Ceccaldi A, Haymann JP, Guedeney P, Nicolas-Jilwan F, Zeitouni M, Montalescot G, Lionnet F, Isnard R, Hatem SN. Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anaemia patients. Eur J Clin Invest. 2021 Aug 14;e13664. doi: 10.1111/eci.13664. Epub 2021 Aug 14. PMID: 34390499.
Copy Download .nbib Format: NLM
2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y.

European cardiology

Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G.
PMID: 33708263
Eur Cardiol. 2021 Mar 02;16:e02. doi: 10.15420/ecr.2020.40. eCollection 2021 Feb.

The unique characteristics of patients with acute coronary syndrome in the Asia-Pacific region mean that international guidelines on the use of dual antiplatelet therapy (DAPT) cannot be routinely applied to these populations. Newer generation P2Y

Cite
Tan JW, Chew DP, Abdul Kader MAS, et al. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y. Eur Cardiol. 2021;16:e02doi: 10.15420/ecr.2020.40.
Tan, J. W., Chew, D. P., Abdul Kader, M. A. S., Ako, J., Bahl, V. K., Chan, M., Park, K. W., Chandra, P., Hsieh, I. C., Huan, D. Q., Johar, S., Juzar, D. A., Kim, B. K., Lee, C. W., Lee, M. K., Li, Y. H., Almahmeed, W., Sison, E. O., Tan, D., Wang, Y. C., Yeh, S. J., & Montalescot, G. (2021). 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y. European cardiology, 16e02. https://doi.org/10.15420/ecr.2020.40
Tan, Jack Wc, et al. "2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y." European cardiology vol. 16 (2021): e02. doi: https://doi.org/10.15420/ecr.2020.40
Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y. Eur Cardiol. 2021 Mar 02;16:e02. doi: 10.15420/ecr.2020.40. eCollection 2021 Feb. PMID: 33708263; PMCID: PMC7941380.
Copy Download .nbib Format: NLM
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.

Circulation

Vlachojannis GJ, Wilschut JM, Vogel RF, Lemmert ME, Delewi R, Diletti R, van der Waarden NWPL, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC.
PMID: 33315489
Circulation. 2020 Dec 15;142(24):2316-2328. doi: 10.1161/CIRCULATIONAHA.120.051532. Epub 2020 Oct 14.

BACKGROUND: Early treatment with a potent oral platelet P2YMETHODS: We conducted a randomized controlled, multicenter trial in the Netherlands, enrolling patients with ST-segment-elevation myocardial infarction scheduled to undergo pPCI. Patients were randomly allocated to receive in the ambulance, before...

Cite
Vlachojannis GJ, Wilschut JM, Vogel RF, et al. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation. 2020;142(24):2316-2328doi: 10.1161/CIRCULATIONAHA.120.051532.
Vlachojannis, G. J., Wilschut, J. M., Vogel, R. F., Lemmert, M. E., Delewi, R., Diletti, R., van der Waarden, N. W. P. L., Nuis, R. J., Paradies, V., Alexopoulos, D., Zijlstra, F., Montalescot, G., Angiolillo, D. J., Krucoff, M. W., Van Mieghem, N. M., & Smits, P. C. (2020). Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation, 142(24), 2316-2328. https://doi.org/10.1161/CIRCULATIONAHA.120.051532
Vlachojannis, Georgios J, et al. "Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial." Circulation vol. 142,24 (2020): 2316-2328. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051532
Vlachojannis GJ, Wilschut JM, Vogel RF, Lemmert ME, Delewi R, Diletti R, van der Waarden NWPL, Nuis RJ, Paradies V, Alexopoulos D, Zijlstra F, Montalescot G, Angiolillo DJ, Krucoff MW, Van Mieghem NM, Smits PC. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. Circulation. 2020 Dec 15;142(24):2316-2328. doi: 10.1161/CIRCULATIONAHA.120.051532. Epub 2020 Oct 14. PMID: 33315489.
Copy Download .nbib Format: NLM
How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators.

Panminerva medica

Sabouret P, Angoulvant D, Pathak A, Fysekidis M, Laterra G, Costa F, Montalescot G, Biondi-Zoccai G.
PMID: 34060278
Panminerva Med. 2021 Jun 01; doi: 10.23736/S0031-0808.21.04284-1. Epub 2021 Jun 01.

The continuous progress in cardiovascular (CV) risk prevention strategies has led to an impressive reduction in mortality and recurrent ischemic events in patients with coronary artery disease (CAD). However, the control of several CV risk factors remains suboptimal in...

Cite
Sabouret P, Angoulvant D, Pathak A, et al. How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. Panminerva Med. 2021;doi: 10.23736/S0031-0808.21.04284-1.
Sabouret, P., Angoulvant, D., Pathak, A., Fysekidis, M., Laterra, G., Costa, F., Montalescot, G., & Biondi-Zoccai, G. (2021). How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. Panminerva medica, . https://doi.org/10.23736/S0031-0808.21.04284-1
Sabouret, Pierre, et al. "How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators." Panminerva medica vol. (2021). doi: https://doi.org/10.23736/S0031-0808.21.04284-1
Sabouret P, Angoulvant D, Pathak A, Fysekidis M, Laterra G, Costa F, Montalescot G, Biondi-Zoccai G. How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. Panminerva Med. 2021 Jun 01; doi: 10.23736/S0031-0808.21.04284-1. Epub 2021 Jun 01. PMID: 34060278.
Copy Download .nbib Format: NLM
The Cornelian dilemma† of quitting DAPT.

European heart journal

Motovska Z, Montalescot G.
PMID: 34686872
Eur Heart J. 2021 Dec 01;42(45):4635-4637. doi: 10.1093/eurheartj/ehab658.

No abstract available.

Cite
Motovska Z, Montalescot G. The Cornelian dilemma† of quitting DAPT. Eur Heart J. 2021;42(45):4635-4637doi: 10.1093/eurheartj/ehab658.
Motovska, Z., & Montalescot, G. (2021). The Cornelian dilemma† of quitting DAPT. European heart journal, 42(45), 4635-4637. https://doi.org/10.1093/eurheartj/ehab658
Motovska, Zuzana, and Montalescot, Gilles. "The Cornelian dilemma† of quitting DAPT." European heart journal vol. 42,45 (2021): 4635-4637. doi: https://doi.org/10.1093/eurheartj/ehab658
Motovska Z, Montalescot G. The Cornelian dilemma† of quitting DAPT. Eur Heart J. 2021 Dec 01;42(45):4635-4637. doi: 10.1093/eurheartj/ehab658. PMID: 34686872; PMCID: PMC8634556.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 44 entries